4.6 Article

Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study

Journal

BMJ OPEN
Volume 9, Issue 12, Pages -

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2019-031947

Keywords

-

Funding

  1. NIA [U01 AG024904]
  2. Easton Consortium for Alzheimer's Drug Discovery and Biomarker Development - Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  3. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  4. National Institute on Aging
  5. National Institute of Biomedical Imaging and Bioengineering
  6. Alzheimer's Association
  7. Alzheimer's Drug Discovery Foundation
  8. Araclon Biotech
  9. Biogen
  10. Bristol-Myers Squibb Company
  11. CereSpir, Inc
  12. Cogstate
  13. Eisai Inc
  14. Elan Pharmaceuticals, Inc
  15. Eli Lilly and Company
  16. EuroImmun
  17. F. Hoffmann-La Roche Ltd
  18. Fujirebio
  19. IXICO Ltd
  20. Johnson & Johnson Pharmaceutical Research & Development LLC
  21. Meso Scale Diagnostics, LLC
  22. Novartis Pharmaceuticals Corporation
  23. Pfizer Inc
  24. Piramal Imaging
  25. Canadian Institutes of Health Research
  26. ADNI clinical sites in Canada
  27. Foundation for the National Institutes of Health
  28. Northern California Institute for Research and Education
  29. Laboratory for Neuro Imaging at the University of Southern California

Ask authors/readers for more resources

Objective To investigate the relationship between amyloid burden and frequency of existing and incidence of new neuropsychiatric symptoms (NPS) in elderly with and without cognitive decline. Methods 275 cognitively normal controls (NC), 100 subjective memory complaint (SMC), 559 mild cognitive impairment (MCI) and 143 Alzheimer's disease dementia subjects from the Alzheimer's Disease Neuroimaging Initiative received (F-18)-florbetapir positron emission tomography (PET) scans. Yearly neuropsychiatric inventory (Neuropsychiatric Inventory (NPI)/NPI-Questionnaire) data were collected from the study partners at each visit. Mean standard uptake volume ratios (SUVR) normalised to whole cerebellum were obtained. Positive amyloid PET scan was defined as mean SUVR >= 1.17. Fisher's exact test was used to compare frequency and incidence between amyloid positive and amyloid negative subjects. Survival analyses were used to estimate of neuropsychiatric symptoms (NPS) between amyloid positive and amyloid negative subjects. Survival analyses were used to estimate hazard ratios for developing the most common NPS by amyloid status. Results No differences in NPS frequency were seen between amyloid positive and amyloid negative NC, SMC, MCI or dementia groups. MCI subjects with amyloid pathology however tended to have greater frequency x severity (FxS) of anxiety, hallucinations, delusions, apathy, disinhibition, irritability, aberrant motor behavior, and appetite, but not agitation, depression, night-time disturbances, or elation. MCI subjects with amyloid pathology were at greater risk for developing apathy, anxiety and agitation over time. Baseline presence of agitation and apathy and new onset agitation, irritability and apathy predicted faster conversion to dementia among MCI subjects. Conclusions Amyloid pathology is associated with greater rate of development of new NPS in MCI. Anxiety and delusions are significant predictors of amyloid pathology. Agitation, irritability and apathy are significant predictors for conversion from MCI to dementia.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available